Ascend Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Ascend Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-40,252	Closed	-$1.02M	–	242
2017 Q3	$1.02M	Buy	+40,252	New	+$979K	0.04%	151

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ascend Capital's RIGL Position: Q4 2017 in Review

Ascend Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2017, closing a stake of 40,252 shares — an estimated $1.02M sold.

Ascend Capital first reported a position in RIGL in Q3 2017 and held it in 1 quarter. The position peaked at $1.02M in Q3 2017. 121 funds tracked by Wall St. Rank hold RIGL as of Q4 2017.

Ascend Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 40,252 Rigel Pharmaceuticals shares in Q4 2017, an estimated $1.02M.
Ascend Capital first reported a position in Rigel Pharmaceuticals in Q3 2017 and held it in 1 quarter.
Ascend Capital's Rigel Pharmaceuticals position peaked at $1.02M in Q3 2017.
121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.